The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

Acta Oncol. 2019 Jun;58(6):897-900. doi: 10.1080/0284186X.2019.1588992. Epub 2019 Mar 25.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Abdominal Neoplasms / drug therapy*
  • Adenomatous Polyposis Coli / drug therapy*
  • Adult
  • Aminopyridines / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
  • Female
  • Fibromatosis, Aggressive / drug therapy*
  • Goserelin / therapeutic use
  • Humans
  • Letrozole / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Purines / therapeutic use*
  • Young Adult

Substances

  • Aminopyridines
  • Protein Kinase Inhibitors
  • Purines
  • Goserelin
  • Letrozole
  • CDK4 protein, human
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • ribociclib

Supplementary concepts

  • Desmoid disease, hereditary